期刊文献+

PI3K/Akt信号通路与肿瘤血管新生的研究进展 被引量:33

The progress of PI3K/Akt signaling pathway and tumor angiogenesis
在线阅读 下载PDF
导出
摘要 PI3K/Akt信号通路在多种细胞中活化,参与细胞的增殖、分化、凋亡、血管新生等病理、生理过程。血管的生成需要PI3K/Akt信号通路的激活,PI3K/Akt活化后可以广泛诱导鸡胚尿囊膜血管的生成。PI3K/Akt信号通路与其下游信号分子m TOR及多种促血管新生因子,如VEGF、HIF等相互作用,从而促进肿瘤血管新生。PI3K/Akt信号通路抑制剂能够抑制其血管新生作用,因此靶向PI3K/Akt信号通路为恶性肿瘤靶向治疗提供了新方法。 PI3 K/Akt signaling pathway is activated in variety of cells. It is involved in the pathological and physiological processes of cell proliferation,differentiation,apoptosis and angiogenesis. Angiogenesis is required for activation of the PI3 K/Akt signaling pathway,and activation of PI3 K/Akt induces extensive angiogenesis in chick embryo chorioallantoic membranes. The PI3 K/Akt signaling pathway interacts with its downstream signaling molecule m TOR and a variety of angiogenic factors such as VEGF and HIF,then enhancing tumor angiogenesis. Inhibitors of PI3 K/Akt signaling pathway can inhibit their angiogenesis,so targeting PI3 K/Akt signaling pathway provides a new approach for targeted therapy of malignant tumors.
作者 耿军辉 张丽军 王亚丽 付建珠 齐雪军 成志勇 张金金 Geng Junhui;Zhang Lijun;Wang Yali;Fu Jianzhu;Qi Xuejun;Cheng Zhiyong;ZhangJinjin(People's Hospital of Dingzhou , Hebei Dingzhou 073000, China;Chengde Medical University, Hebei Chengde 067000, China;The No. 1 Hospital of Baoding, Hebei Baoding 071000, China.)
出处 《现代肿瘤医学》 CAS 2018年第9期1462-1466,共5页 Journal of Modern Oncology
基金 河北省重点科技计划项目(编号:162777120D)
关键词 PI3K AKT MTOR VEGF 血管新生 PI3K, Akt, mTOR, VEGF, angiogenesis
  • 相关文献

参考文献4

二级参考文献87

  • 1成志勇,潘崚,牛志云,梁文同,贾志强,颜晓燕,姚丽,杨敬慈.PTEN基因转染对白血病细胞VEGF调控作用的影响[J].肿瘤,2010,30(10):815-821. 被引量:17
  • 2Shibuya M.Vascular endothelial growth factor-dependent and-independent regulation of angiogenesis.BMB Rep,2008,41(4):278-286.
  • 3Kiba A.Sagara H,Hara T,et al.VEGFR-2-specific ligand VEGF-E induces non-edematous hyper vascularization in mice.Biochem Biophys Res Commun,2003,301(2):371-377.
  • 4Yamazaki Y,Takani K,Atoda H,et al.Snake venom vascular endothelial growth factors(VEGFs)exhibit potent activity through their specific recognition of KDR(VEGF receptor 2).J Biol Chem,2003,278(52):51985-51988.
  • 5Carmeliet P,Ferreira V,Breier G,et al.Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele.Nature,1996,380(6573):435-439.
  • 6Carmeliet P,Moons L,Dewerchin M,et al.Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor,the tissue factor receptor,and the plasminogen system.Ann N Y Acad Sci,1997,811:191-206.
  • 7Vincenti V,Cassano C,Rocchi M,et al.Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3.Circulation,1996,93(8):1493-1495.
  • 8Zygalaki E,Kaklamanis L,Nikolaou N I,et al.Expression profile of total VEGF.VEGF splice variants and VEGF receptors in the myocardium and arterial vasculature of diabetic and non-diabetic patients with coronary artery disease.Clin Biochem,2008,41(1-2):82-87.
  • 9Liu L,Simon M C.Regulation of transcription and translation by hypoxia.Cancer Biol Ther,2004,3(6):492-497.
  • 10Kawamura H,Li X,Harper S J,et al.Vascular endothelial growth factor(VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity.Cancer Res,2008,68(12):4683-4692.

共引文献62

同被引文献396

引证文献33

二级引证文献167

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部